Physician profile
Robert W Sugerman
NPI 1598759862
$9,254.96
in general payments reported to CMS, 2019-2025
36 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $261 · 2021: $434 · 2022: $943 · 2023: $1,337 · 2024: $4,185 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,245 · Honoraria: $2,500 · Travel and Lodging: $250 · Education: $34.00 · Consulting Fee: $27.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,244.53 |
| Honoraria | $2,500.00 |
| Travel and Lodging | $250.00 |
| Education | $34.00 |
| Consulting Fee | $27.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $2,822.07 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $717.30 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $627.82 | 2019-2025 | Dupixent |
| Pfizer INC. | $607.38 | 2020-2025 | |
| Genzyme Corporation | $473.87 | 2021-2025 | |
| Csl Behring | $422.63 | 2019-2025 | Hizentra, Privigen |
| Consortium of Independent Immunology Clinics, LLC | $400.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $339.84 | 2019-2025 | Fasenra, Evusheld, Tezspire |
| Octapharma USA, INC. | $332.59 | 2022-2025 | Octagam Immune Globulin (Human), Cutaquig, Panzyga |
| Grifols USA, LLC | $309.89 | 2020-2025 | Xembify, Gamunex-C |
| Glaxosmithkline, LLC. | $277.08 | 2019-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $232.72 | 2019-2025 | |
| Kaleo, INC. | $225.55 | 2020-2023 | Auvi-Q |
| Genentech USA, INC. | $186.52 | 2023-2025 | Xolair |
| Pharming Healthcare, INC. | $145.70 | 2022-2025 | Ruconest |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $129.77 | 2022-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $104.54 | 2025 | Neffy |
| Optinose US, INC. | $83.83 | 2019-2025 | |
| Phadia US INC. | $81.47 | 2020-2023 | Immunocap |
| Hospira, INC. | $79.96 | 2024-2025 | |
| Covis Pharma Gmbh | $71.81 | 2019-2022 | |
| Organon LLC | $65.13 | 2025 | Vtama |
| Teva Pharmaceuticals USA, INC. | $64.31 | 2020-2022 | |
| Blueprint Medicines Corporation | $62.41 | 2023-2025 | Ayvakit |
| Azurity Pharmaceuticals, INC. | $61.20 | 2025 | Alvesco |
| Gc Biopharma USA, INC. | $54.62 | 2024-2025 | Alyglo, Alyglo |
| Leo Pharma INC. | $48.44 | 2025 | Adbry, Anzupgo |
| Kedrion Biopharma, INC. | $47.53 | 2024 | Gammaked, Kedrab, Koate |
| Ani Pharmaceuticals, INC. | $28.94 | 2023 | Purified Cortrophin Gel |
| Shire North American Group INC | $28.07 | 2019 | |
| Insmed, INC. | $22.87 | 2025 | Arikayce |
| Galderma Laboratories, L.P. | $22.00 | 2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $20.65 | 2020 | |
| Hikma Pharmaceuticals USA | $19.74 | 2023 | Ryaltris |
| Tersera Therapeutics LLC | $19.29 | 2023 | Quzyttir |
| Ionis Pharmaceuticals, INC. | $17.42 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$49,470.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sugerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.